Seeking Alpha

Soligenix (SNGX.OB) completes a Phase 1 study of its pediatric Crohn's disease treatment SGX203...

Soligenix (SNGX.OB) completes a Phase 1 study of its pediatric Crohn's disease treatment SGX203 which has Fast Track and Orphan Drug designation from the FDA. The study helped to "characterize the pharmacokinetic and pharmacodynamic" profile of the formula. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)